<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7256510\results\search\testTrace\results.xml">
  <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2). â€¢The current knowledge about the" exact="treatment" post="protocol is still limited. â€¢Preventing the virus can be"/>
  <result pre="Despite intense research efforts worldwide, an effective vaccine and viable" exact="treatment" post="options have eluded investigators. Therefore, infection prevention, early viral"/>
  <result pre="effective vaccine and viable treatment options have eluded investigators. Therefore," exact="infection" post="prevention, early viral detection and identification of successful treatment"/>
  <result pre="treatment options have eluded investigators. Therefore, infection prevention, early viral" exact="detection" post="and identification of successful treatment protocols provide the best"/>
  <result pre="Therefore, infection prevention, early viral detection and identification of successful" exact="treatment" post="protocols provide the best approach in controlling disease spread."/>
  <result pre="world. A mathematical model examined whether the control of SARS-CoV-2" exact="infection" post="could be achieved by isolating affected patients, and tracking"/>
  <result pre="be too much delay between the onset of symptoms and" exact="isolation" post="[6]. Thus, observing preventive measures, especially isolation and lockdown,"/>
  <result pre="of symptoms and isolation [6]. Thus, observing preventive measures, especially" exact="isolation" post="and lockdown, would be essential. SARS-CoV-2 is highly contagious,"/>
  <result pre="and there has not yet been any vaccine or effective" exact="treatment" post="that has received approval. So, the best solution for"/>
  <result pre="develop COVID-19 as adults [24]. So, prevention and finding appropriate" exact="treatment" post="for children is as important as for adults. In"/>
  <result pre="recommended. The reported contagion rates from a patient with symptomatic" exact="infection" post="vary by location and efficiency of infection control measures."/>
  <result pre="patient with symptomatic infection vary by location and efficiency of" exact="infection" post="control measures. Based on a joint WHO-China report, the"/>
  <result pre="on a joint WHO-China report, the rate of secondary COVID-19" exact="infection" post="ranged from one to five percent among tens of"/>
  <result pre="appear to be an important factor in the spread of" exact="infection" post="[30]. It should be mentioned that a study of"/>
  <result pre="an autopsy) two days after the owner was in COVID-19" exact="quarantine" post="[46]. So, possible animal-to-human transmission of the virus must"/>
  <result pre="The virus is highly contagious, and there is no successful" exact="treatment" post="or a vaccine. Also, a relatively long incubation period,"/>
  <result pre="viral shedding after recovery all underline the importance of home" exact="quarantine" post="through lockdown of the entire society like the Chinese"/>
  <result pre="government carried out [47]. 6 Temperature and humidity and SARS-CoV-2" exact="infection" post="One study investigated the relationship between the mean daily"/>
  <result pre="has stated that education, isolation, prevention, controlling the transmission, and" exact="treatment" post="of infected persons are the critical steps in controlling"/>
  <result pre="COVID-19 [52]. It is possible to minimize the spread of" exact="infection" post="by making the following recommendations. Staying at home (home"/>
  <result pre="person, which has been called shielding; avoiding nonessential travel; observing" exact="social distancing" post="rules like avoiding crowded public places and maintaining at"/>
  <result pre="of hands is the best way to protect against SARS-CoV-2" exact="infection" post="[55]. A study in six departments of a hospital"/>
  <result pre="by doctors and nurses were effective in preventing against COVID-19" exact="infection" post="[56]. In terms of vaccines, there are a large"/>
  <result pre="vaccine against SARS-CoV-2, several clinical trials have been launched for" exact="testing" post="the effects of various vaccines against SARS-CoV-2. 8 COVID-19"/>
  <result pre="with intractable hypoxemia. So, the treatments of patients with COVID-19" exact="infection" post="are mainly symptomatic in nature. It should be mentioned"/>
  <result pre="trial data, Interferons because of lack of efficacy in the" exact="treatment" post="of SARS and MERS, Janus kinase inhibitors (e.g., Baricitinib"/>
  <result pre="of their broad immunosuppressive effects, and systemic corticosteroids during the" exact="treatment" post="of mechanically ventilated patients with COVID-19 without ARDS. Scientists"/>
  <result pre="the cap-dependent endonuclease) (ChiCTR2000029544). 8.1.1.2 Favilavir Favilavir is an approved" exact="treatment" post="for Influenza, which inhibits the RNA-dependent RNA polymerase. It"/>
  <result pre="Drug Administration (FDA) has approved Remdesivir as an effective COVID-19" exact="treatment" post="[78]. 8.1.1.5 Galidesivir (BCX4430) Galidesivir is an adenosine analog"/>
  <result pre="against COVID-19. However the application of this drug as a" exact="treatment" post="for COVID-19 requires clinical trials [95]. 8.1.1.6.7 Griffithsin Griffithsin"/>
  <result pre="Arbidol Arbidol is a nonâ€�nucleoside antiviral and immunomodulatory drug for" exact="treatment" post="and prevention of influenza, which could be effective against"/>
  <result pre="is an anti-malarial drug [100] with practical activity against SARS-CoV-2" exact="infection" post="[101], which could help in the treatment of COVID-19."/>
  <result pre="activity against SARS-CoV-2 infection [101], which could help in the" exact="treatment" post="of COVID-19. It has immunomodulatory effects, such as suppression"/>
  <result pre="type of autophagy inhibitor [102], which probably interferes with viral" exact="infection" post="and replication. Moreover, scientists have reported in a number"/>
  <result pre="one of three drugs that could be promising for the" exact="treatment" post="of new coronavirus disease; the other two drugs, described"/>
  <result pre="[105], where the percentage of patients with a negative viral" exact="nucleic acid test" post="was higher with anti-malarial drugs. Until now, no severe"/>
  <result pre="the combination of HCQ plus Azithromycin c was an effective" exact="treatment" post="of COVID-19 [109], the NIH has not recommended it"/>
  <result pre="[109], the NIH has not recommended it as a routine" exact="treatment" post="for clinical use due to the potential for toxicity."/>
  <result pre="convalescent plasma therapy Plasma antibodies contribute to the elimination of" exact="infection" post="via directly binding to pathogens and neutralizing them, or"/>
  <result pre="(CP) is a passive-adaptive-immunotherapy applied to protect individuals from clinical" exact="infection" post="or prevent disease development. The early administration of CP"/>
  <result pre="test, the absence of symptoms, normal physical examination, and pre-donation" exact="screening" post="assays. It should be mentioned that since plasma with"/>
  <result pre="transfusion reactions could be risks of plasma therapy in the" exact="treatment" post="of COVID-19 [147], [148]. It must be mentioned that"/>
  <result pre="membrane fusion, and sialic acid-binding sites), and reduce replication and" exact="infection" post="progression. Some mAbs that target the spike protein in"/>
  <result pre="in COVID-19 patient improvement. Besides, 47D11 could powerfully suppress the" exact="infection" post="of SARS-CoV and SARS-CoV-2 through an unknown mechanism [155]."/>
  <result pre="viral infections [75]. For example, SAB-301 is a well-tolerated antiviral" exact="treatment" post="for MERS-CoV [158]. So, polyclonal antibodies might also be"/>
  <result pre="Anakinra, a recombinant Interleukin-1 receptor antagonist, was studied in the" exact="treatment" post="of COVID-19. In this study, 29 patients received the"/>
  <result pre="patients received the drug, while 16 patients received only standard" exact="treatment" post="for COVID-19. Twenty-one patients (72%) of the intervention group"/>
  <result pre="COVID-19 and improve respiratory status, and may be an effective" exact="treatment" post="[165]. 8.9 Ibuprofen Ibuprofen has shown problems with safety"/>
  <result pre="over the safety of non-steroidal anti-inflammatory drugs (NSAIDs) in the" exact="treatment" post="of COVID-19 has involved the European Medicines Agency. It"/>
  <result pre="one and two clinical trials (2017), could significantly inhibit COVID-19" exact="infection" post="in the early stage and prevent the virus from"/>
  <result pre="can also be a suitable tool for nucleic acid sequence" exact="detection" post="[172]. In addition, since Cas13 and inactive Cas13 target"/>
  <result pre="COVID-19. 8.17 Ivermectin Ivermectin is an FDA-approved drug for the" exact="treatment" post="of parasitic amnesia, which is widely available. It was"/>
  <result pre="has an immunomodulatory effect, and is commonly used in the" exact="treatment" post="of gout. Due to its immunomodulatory effects, it could"/>
  <result pre="blocking antibodyÂ +Â standard treatment, ThymosinÂ +Â standard treatment, standard" exact="treatment" post="NCT04268537 Not yet recruiting Tocilizumab vs. CRRT in Management"/>
  <result pre="novel and highly contagious virus, and there is no specific" exact="treatment" post="for COVID-19 disease up to now. It must be"/>
  <result pre="patient tracking measures are not widely implemented or effective, intermittent" exact="social distancing" post="is likely to continue until 2022. By that time"/>
  <result pre="Journal Publishing Group; 2020. 6HellewellJ.AbbottS.GimmaA.BosseN.I.JarvisC.I.RussellT.W.Feasibility of controlling COVID-19 outbreaks by" exact="isolation" post="of cases and contacts.The Lancet Global Health.2020 7MohamedK.RodrÃ­guez-RomÃ¡nE.RahmaniF.ZhangH.IvanovskaM.MakkaS.A.Borderless collaboration"/>
  <result pre="Wuhan, China: a descriptive studyThe Lancet.395102232020507513 17CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, evaluation and" exact="treatment" post="coronavirus (COVID-19). Statpearls [internet]StatPearls Publishing2020 18(WHO) WHO. Q&amp;amp;A on"/>
  <result pre="MS, Bloom A (Eds) Accessed Mar. 2020;5. 31RotheC.SchunkM.SothmannP.BretzelG.FroeschlG.WallrauchC.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN. Engl. J. Med.2020"/>
  <result pre="contact in GermanyN. Engl. J. Med.2020 32YuP.ZhuJ.ZhangZ.HanY.HuangL.A familial cluster of" exact="infection" post="associated with the 2019 novel coronavirus indicating potential person-to-person"/>
  <result pre="20 [Available from: https://www.straitstimes.com/asia/east-asia/second-dog-in-hong-kong-tests-positive-for-coronavirus. 47Wilder-Smith A, Freedman D. Isolation, quarantine," exact="social distancing" post="and community containment: pivotal role for old-style public health"/>
  <result pre="delta T lymphocytes in breast cancer: a reviewTranslational Research.2032019889630194922 59SaghazadehA.RezaeiN.Towards" exact="treatment" post="planning of COVID-19: Rationale and hypothesis for the use"/>
  <result pre="Guidelines 2020 April 21 [Available from: https://covid19treatmentguidelines.nih.gov/introduction/. 62RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseThe lancet.395102232020e30e31 63WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of"/>
  <result pre="of Hemorrhagic Fever Virus Infections. Chemistryâ€&quot;An Asian Journal. 2019;14(22):3962-8. 68OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful" exact="treatment" post="of advanced Ebola virus infection with T-705 (favipiravir) in"/>
  <result pre="Chemistryâ€&quot;An Asian Journal. 2019;14(22):3962-8. 68OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful treatment of advanced Ebola virus" exact="infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.1052014172124583123"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discovery6120201431934347 78(FDA) FaDA. Coronavirus (COVID-19) Update: FDA"/>
  <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
  <result pre="COVID-19 infection in Korea: the application of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 infected pneumonia monitored by quantitative RT-PCRJ. Korean"/>
  <result pre="2020. 89ChenY.W.YiuC.-P.WongK.-Y.Prediction of the 2019-nCoV 3C-like protease (3CLpro) structure: virtual" exact="screening" post="reveals velpatasvir, ledipasvir, and other drug repurposing candidatesChemRxiv2020 90ParkJ.-Y.JeongH.J.KimJ.H.KimY.M.ParkS.-J.KimD.Diarylheptanoids"/>
  <result pre="Drug Resistance.83201845946430396013 101VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirology journal.2120056916115318 102GoldenE.B.ChoH.-Y.HofmanF.M.LouieS.G.SchÃ¶nthalA.H.ChenT.C.Quinoline-based antimalarial drugs: a novel class"/>
  <result pre="chloroquine and hydroxychloroquineScand. J. Rheumatol.3219741031084608161 109GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
  <result pre="Huang S-Y, Xiao Y. Molecular mechanism of evolution and human" exact="infection" post="with the novel coronavirus (2019-nCoV). bioRxiv. 2020. 115LiuT.ZhangJ.YangY.ZhangL.MaH.LiZ.The potential"/>
  <result pre="novel T-cell engaging therapiesCurr. Opin. Pediatr.26120144324362408 120LiX.GengM.PengY.MengL.LuS.Molecular immune pathogenesis and" exact="diagnosis" post="of COVID-19J. Pharm. Anal.2020 121BellT.J.BrandO.J.MorganD.J.Salek-ArdakaniS.JaggerC.FujimoriT.Defective lung function following influenza"/>
  <result pre="138Mair-JenkinsJ.Saavedra-CamposM.BaillieJ.K.ClearyP.KhawF.-M.LimW.S.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="medRxiv. 2020. 158MomattinH.Al-AliA.Y.Al-TawfiqJ.A.A Systematic Review of therapeutic agents for the" exact="treatment" post="of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)Travel Med."/>
  <result pre="new patients?Int. J. Mol. Sci.21720202272 160De RanieriD.FennyN.S.Intravenous immunoglobulin in the" exact="treatment" post="of primary immunodeficiency diseasesPediatr. Ann.4612017e8e1228079912 161GaleottiC.KaveriS.V.BayryJ.IVIG-mediated effector functions in"/>
  <result pre="autoimmune and inflammatory diseasesInt. Immunol.2911201749149828666326 162WangJ.-T.ShengW.-H.FangC.-T.ChenY.-C.WangJ.-L.YuC.-J.Clinical manifestations, laboratory findings, and" exact="treatment" post="outcomes of SARS patientsEmerg. Infect. Dis.105200481815200814 163ArabiY.M.ArifiA.A.BalkhyH.H.NajmH.AldawoodA.S.GhabashiA.Clinical course and"/>
  <result pre="proteins Csx27 and Csx28. Molecular cell. 2017;65(4):618-30. e7. 172GootenbergJ.S.AbudayyehO.O.LeeJ.W.EssletzbichlerP.DyA.J.JoungJ.Nucleic acid" exact="detection" post="with CRISPR-Cas13a/C2c2Science3566336201743844228408723 173LuQ.ShiY.Coronavirus disease (COVID-19) and neonate: What neonatologist"/>
  <result pre="Grassi LG, et al. Protocol for a randomized controlled trial" exact="testing" post="inhaled nitric oxide therapy in spontaneously breathing patients with"/>
  <result pre="with COVID-19. medRxiv. 2020. 175OrganizationW.H.Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected: interim guidance, 13"/>
  <result pre="Health Organization 176Nowak JK, Walkowiak J. Is lithium a potential" exact="treatment" post="for the novel Wuhan (2019-nCoV) coronavirus? A scoping review."/>
  <result pre="use of methotrexate, colchicine, and other immunomodulatory drugs in the" exact="treatment" post="of primary biliary cirrhosis. Seminars in liver disease; 1997:"/>
 </snippets>
</snippetsTree>
